<DOC>
	<DOC>NCT01012895</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who have not responded to prior therapy.</brief_summary>
	<brief_title>Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male and female subjects ages 18 to 70 years HCVInfected Genotype 1 Null responders to current standard of care Expansion Cohorts A1 and A2 are restricted to patients infected with HCV Genotype 1b only. Evidence of a medical condition associate with chronic liver disease other than HCV History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis History of Cancer within 5 years of enrollment History of gastrointestinal disease or surgical procedure (except Cholecystectomy) History of clinically significant cardiac disease History of Glucose6phosphate dehydrogenase (G6PD) deficiency Documented cirrhosis within 12 months prior to dosing Positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV) Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>